

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



FOUNDING SPONSOR



PARTNERING LOGIN



GOLD SPONSORS



Barrington  
James



McDermott  
Will & Emery

[www.anglonordiclifescience.com](http://www.anglonordiclifescience.com)



etcvenues | Password: wifi3052



@Anglonordic



At M Ventures we invest in transformational ideas driven by innovative entrepreneurs. We team up to translate scientific discoveries into commercial success.



# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

**Dear Delegate,**

We are delighted to welcome you to the eighteenth annual Anglonordic Life Science Conference in London.

It feels wonderful that we are finally back to a face-to-face conference again this year. The last time was 9th of May 2019. I repeat, May 2019... That is a long time ago. In 2020 we unfortunately had to cancel the conference, for reasons we know and would like to forget. Last year the 2021 conference, despite being held digitally, was a great success. This year the Anglonordic Life Science Conference is one of the first face-to-face conferences in Europe within the life science sector.

This is the conference's third year at the iconic venue County Hall, one of London's most recognizable buildings, across the River Thames from the Houses of Parliament.

The main six storey building was opened in 1922 by King George V and the North and South blocks were added between 1936 and 1939. For 64 years County Hall served as the headquarters of local government for London. During the 1980s the then powerful Labour-controlled GLC (Greater London Council) led by Ken Livingstone was locked in conflict with the Conservative government of Margaret Thatcher. When the government abolished the GLC in 1986, County Hall remained in use by the Inner London Education Authority (ILEA) until its abolition in 1990 when the building was eventually sold to private investors.

The 3rd and 4th floor event space was opened in 2017 and is managed by an experienced operator. If you have any questions or access problems, staff are on site to assist.

The Anglonordic Life Science Conference continues with its "by invitation only policy" and gives you the opportunity to meet R&D companies, international pharmaceuticals and investment firms.

We would sincerely like to thank our sponsors such as our Founding sponsor M Ventures and Gold sponsors Barrington James and McDermott Will & Emery!

Once again we welcome you to the 18th Anglonordic Life Science Conference for a day of unique collaboration opportunities.

Yours sincerely,

Anglonordic Life Science Conference Team

**Mr Mattias Johansson**  
Founder, Anglonordic Life Science Conference



# ANGLO NORDIC | LIFE SCIENCE CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## FOUNDING SPONSOR



## GOLD SPONSORS



**Barrington  
James**



**McDermott  
Will & Emery**

## SILVER SPONSORS



## BRONZE SPONSOR



## SUPPORTING SPONSORS



## MEDIA PARTNERS



# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Contents

Welcome	3
Keynote	9
Investor Panel	10 - 11
McDermott Will & Emery Workshop	12
Company Presentations	13 - 16
RNA in the Spotlight Panel	16 - 17
Company Presentations	17 - 19
Neuroinflammation Panel	20 - 21
If I knew then what I know now Panel	21 - 23
Conclusions	23
Charity of the Year	24
Exhibitors	26 - 27
Venue Map	30

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

**08:15 - 09:00 Registration**

**09:00 - 09:05 Welcome from the Conference Founder**

**Mattias Johansson**, Director, Ezenze

**09:05 - 09:30 Keynote**

**Gil Bar-Nahum**, Managing Director - EMEA Head of Biotechnology, Jefferies

**09:30 - 10:15 Panel Discussion: Trends in Life Science Investments**

**Chaired by: Stephen Hansen**, Associate Editor, BioCentury

**Panellists: Hakan Goker**, Managing Director, M Ventures,

**Henriette Richter**, Managing Partner, Sofinnova Partners,

**Marten Steen**, Managing Partner, HealthCap, **Roel Bulthuis**,

Managing Director, INKEF Capital, **Søren Møller**, Managing

Partner, Novo Holdings

**10:15 - 10:30 Coffee Break, Exhibition, Networking**

**10:30 - 11:00 Workshop: Venture Capital and Collaborations in the Life Sciences Sector – Overview of Investment Rounds and Licensing Arrangements**

**Workshop Instructors: Arvin Abraham**, Partner, McDermott Will & Emery and **Gary Howes**, Counsel, McDermott Will & Emery

**11:00 - 12:30 Company Presentations: Morning Session**

**Biotech Investment Room**

Chaired by: **Juan R. Garcia**, Biotechnology Business Institute

*Presentations include:* Vivesto, Cbio A/S, Trobix Innovation Ltd,

Sartar Therapeutics, Paras Biopharmaceuticals Finland Oy, Lytix

**Technology Room**

Chaired by: **Gwyn Tudor**, MediWales and Life Science Industry

*Presentations include:* Oxford Endovascular, Wellthy Therapeutics, Curapel,

Flash Diagnostics, NanoSyrinx, Parkinsongs

**12:30 - 13:00 Lunch, Exhibition, Networking**

# ANGLO NORDIC | LIFE SCIENCE CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

**13:00 - 13:45 Panel Discussion: RNA in the Spotlight**  
**Chaired by:** **Donna Hackett**, Head of Commercial Translation, The Francis Crick Institute  
**Panellists:** **Ralph Lindemann**, Global Head, Translational and Biomarker Research, TIP Oncology & Immunooncology, Merck, **Steven Powell**, CEO, eTheRNA, **Oliver Rausch**, Chief Scientific Officer, STORM Therapeutics

**13:45 - 15:30 Biotech Company Presentations: Afternoon Sessions**  
**Biotech Investment Room**  
**Chaired by:** **Kam Dhaliwal**, SVP Global Strategic Alliances, Bit Bio  
*Presentations include:* Bit Bio, MediSieve, Pharma Holdings AS, Outrun Therapeutics, Phaim Pharma, Scandion, Leadartis  
**Technology Room - incl. Guest Biotech Companies**  
**Chaired by:** **Juan R. Garcia**, Biotechnology Business Institute  
*Presentations include:* Edity Therapeutics, InProTher, Regemat 3D, Mirnax, Biohope, Array For Cell, Immunorizon

**15:30 - 16:00 Coffee Break, Exhibition, Networking**

**16:00 - 16:45 Panel Discussion: Anticipated Developments in Neuroinflammation Therapies**  
**Chaired by:** **Richard Staines**, BioWorld  
**Panellists:** **Stefan Lohmer**, Chairman & CEO, Axxam, **Hugh Nuthall**, Senior Director, Neuroscience Search & Evaluate, Eli Lilly and Company, **Alan Watt**, CSO, NodThera, **Rob Pinnock**, Director External Innovation, Biogen, **Maria Teresa Ferretti**, Co-Founder and Chief Scientific Officer, Women's Brain Project

**16:45 - 17:45 Panel Discussion: If I knew then what I know now**  
**Chaired by:** **Mike Ward**, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate  
**Panellists:** **Khatereh Ahmadi**, Head of Search and Evaluation Team, BD&L Hub, MSD, **Georg Büchner**, CBO, Helsinn Group, **Catherine Moukheibir**, Non Executive Board Member, **Carolyn Porter**, CEO, Cytoseek, **Deborah Spencer**, Senior Manager, Deputy Head of Industry Research Partnerships MPLS, University of Oxford

**17:45 - 17:50 Conclusions**  
**Speakers:** **Hakan Goker**, Managing Director, M Ventures, **Mary Clark**, CEO, Optimum Strategic Communications

**17:50 - 18:30 Drinks Reception - sponsored by Barrington James**

**Hosted by:** **Mattias Johansson**, The Anglonordic Life Science Conference Founder & Director, Ezenze

# GLOBAL LIFE SCIENCE RECRUITMENT SOLUTIONS



PERMANENT | CONTRACT & INTERIM | EXECUTIVE SEARCH  
FSP | RETAINED CAMPAIGN MANAGEMENT | TALENT ACCESS

**VISIT US ON BOOTH: 09**

+44 1293 776644 | [WWW.BARRINGTONJAMES.COM](http://WWW.BARRINGTONJAMES.COM)



# ANGLO NORDIC | LIFE SCIENCE CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Speakers

09:00 - 09:30

### Welcome from the Conference Founder



**Mattias Johansson**

**Director, Ezenze**

Mattias is the Director of Ezenze and the Founder of the Anglonordic Life Science Conference now in its 18th year.

He has over 18 years' experience in the Life Science industry with focus on partnering and investment. Today Mattias is Director and Founder of Ezenze, a management consultancy in Sweden, with a focus on marketing and sponsorship management.

Conference Sessions Chair



**Mary Clark**

**CEO, Optimum Strategic Communications**

Mary has a 20-year successful track record in providing strategic corporate and financial communications to both early and late-stage healthcare companies.

She has run several high profile PR campaigns and has been instrumental in assisting companies with strategic positioning and fundraising rounds from seed and private financings through IPOs, reverse mergers, as well as numerous follow-on public financings.

Mary has worked with over 100 healthcare clients across Europe and the US including Teva Pharmaceutical, Bayer, Fresenius Medical Care, Kite Pharmaceuticals, UDG Healthcare, Evotec and BioNTech.

Mary has built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company's IPO and the start-up of several new tech and biotech companies.

09:05 - 09:30

### Keynote



**Dr Gil Bar-Nahum**

**Managing Director, Jefferies**

Dr. Gil Bar-Nahum is a Managing Director and EMEA Head of Biotechnology in the Global Healthcare Investment Banking Group at Jefferies and is based in London. He leads the team with a primary focus on innovative companies in Europe and Israel.

Dr. Bar-Nahum has over 20 years of investment banking experience and has executed transactions for biotechnology, pharmaceutical, medical technology, and life science tools companies. In the last several years, Dr. Bar-Nahum has led the execution of more than 60 financings, including 30+ IPOs for foreign private issuers (on NASDAQ), raising more than US\$5.0Bn. Since joining Jefferies in 2009, Dr Bar-Nahum has also advised on more than a dozen cross-border M&A transactions including the Advising Vaccibody on their recent partnership with Genentech for approx. \$700m.

From 2002-2009 Dr. Bar-Nahum was part of UBS Investment Bank's Global Healthcare Group, based primarily in the US. Prior to that, Dr. Bar-Nahum worked as an Equity Research Analyst for UBS where he served as an Associate Director covering companies in the Life Science Tools and Biotechnology space. Dr. Bar-Nahum received his PhD in Basic Medical Sciences from the Department of Biochemistry at the Sackler Institute of New York University School of Medicine. The subject of Dr. Bar-Nahum's doctorate work was published twice in the journal Cell. Dr. Bar-Nahum also received an MS from New York University's School of Medicine in Cell and Molecular Biology and a BS from the University of Illinois in Microbiology.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

09:30 - 10:15

## Panel Discussion: Trends in Life Science Investments



**Chaired by Stephen Hansen**  
Associate Editor, BioCentury

Stephen is BioCentury's Associate Editor in the U.K., where he serves as one of the company's primary points of contact with European companies and investors. Stephen has covered clinical development, corporate strategy and finance in Europe, the U.S. and China for BioCentury for over a decade and is a frequent contributor to BioCentury's quarterly Financial Markets Preview and annual Buyside View and European Finance reports. He holds B.A.s in Biology and History from Bethel University and an M.Phil. in History from Oxford University.



**Hakan Goker**  
Managing Director, M Ventures

Hakan Goker, PhD, is Managing Director of M Ventures and heads the Biotechnology investments covering Healthcare and Life Sciences. Hakan joined M Ventures in 2013 and has been investing in the sector for 15 years. Previously, Hakan was a partner at Aescap Venture investing in European opportunities.

Hakan started his investment career at Atlas Venture where he was part of the investment team in London focusing on global investment opportunities in healthcare and medical technologies across US, Europe and Asia. He was instrumental in the creation and financing, business and R&D strategies of multiple companies in their formation years including Orphazyme, Bicycle, Nimbus Discovery, and f-Star while at Aescap and Atlas.

Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continuing his scientific career with post doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London. Hakan is based in Amsterdam at the M Ventures head office.



**Henriette Richter**  
Managing Partner, Sofinnova Partners

Henriette joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitraxe Therapeutics, Nodthera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.

Henriette was attracted by Sofinnova Partners' focus on a positive, consensus-oriented environment and its philosophy of investing in people. "Everyone needs to agree. An individual's success is everyone's success," she says. "And when there's a failure, it's everyone's failure – that fosters different conversations when you consider potential investments."

Prior to Sofinnova, Henriette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).

Henriette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Søren Møller**

**Managing Partner, Novo Holdings**

Søren joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds.

Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.

Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren's tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as Head of Lead Identification at BiImage and as research scientist at Novo Nordisk.

Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reaplix and Northsea Therapeutics. Since 2008, Søren has been a board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).



**Marten Steen**

**Managing Partner, HealthCap**

Prior to re-joining HealthCap as a partner in 2010, Dr. Steen worked with global business development at Merck Serono as a Director, focusing on both product and technology licensing. Prior to Merck Serono, he was a medical associate with HealthCap.

Dr. Steen is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003. He is the author of 16 scientific papers published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.



**Roel Bulthuis**

**Managing Partner & Head of Healthcare Investment, INKEF Capital**

Roel Bulthuis is a Managing Partner and head of the Healthcare investment team at INKEF. Roel combines more than 15 years of experience across venture capital, pharma business development and investment banking.

Prior to joining INKEF he served as an SVP and Managing Director of M-Ventures which he created and developed into a leading CVC fund. Prior to that, he served in senior positions in global business development at Merck Serono and in the investment banking team at Fortis Bank.

Roel is a Kauffman Fellow and passionate about continuously challenging the status quo. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

10:30 - 11:00

## Workshop: Venture Capital and Collaborations in the Life Sciences Sector – Overview of Investment Rounds and Licensing Arrangements



**Arvin Abraham**  
Partner, McDermott Will & Emery

Arvin Abraham focuses his practice on corporate transactions for private equity sponsors and venture capital funds, with a particular focus on the life sciences sector, including the areas of pharma, medical devices and med-tech. On the venture side, his practice focuses on investor side representation and his clients include several leading venture capital funds and corporate venture arms, who he generally represents on complex cross-border venture transactions. Arvin also serves as the Europe representative on McDermott's global venture capital steering committee and is dual qualified as an English solicitor and an attorney in New York.



**Gary Howes**  
Counsel, McDermott Will & Emery

Gary Howes has nearly 25 years of experience advising clients in the life sciences sector on the myriad legal issues that affect this key industry. Gary advises clients on industry specific commercial contracts, patent licensing agreements, alliances, collaborations and technology transfers, IP and regulatory matters and product acquisitions and disposals.

Gary's clients include private and public biotech companies and pharmaceuticals ranging in size and scope from start-ups to established, multinational corporations. He also represents academic and research institutions and serves as a trusted advisor to in-house general counsel and senior executives.

Gary draws on his extensive background to help life sciences clients develop and implement strategies that balance industry-specific laws, competitive pressures and best practices with broader legal, regulatory and market developments. Gary speaks regularly at prominent industry events, having served as a presenter, panellist and moderator at conferences and symposia across Europe and North America.

Gary also advises on intellectual property, including copyright and designs, know-how, inventions and patents, and trade marks, in industries such as publishing, retail, architecture, sportswear, IT, and life sciences. He counsels clients on protection (such as existence and retention of rights, analysis of "chain of title", contractual arrangements to perfect and maintain ownership, etc.) and exploitation (licencing, and assignment, as well as analysis of non-infringing behaviour/action). Prior to joining McDermott, Gary was a Partner at an international law firm, where he founded the firm's life sciences industry group.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

11:00 - 12:30

## Company Presentations Biotech Investment Room



**Chair: Juan R. Garcia**  
**Board Chairman, Biotechnology Business Institute**

Juan's background is based in Management and Molecular Biology applied to innovative biological treatments and new drug discovery processes.

He started his experience at the laboratory in combination with the university degree as oncology researcher assistant at the Medicine College of the University of Barcelona. After the degree he did a master in the pharmaceutical industry and worked as a product manager at the marketing department of AstraZeneca Spain SA., infections disease area.

He has been for more than nine years Managing Partner at the Biotechnology Business Institute. His education and experience during these years have been in business valuation for biotech-based companies, international business development and private funding. Besides, he has experience participating in most relevant Life Sciences conferences and congresses in Europe and The US among others innovation hubs like Israel, Colombia or Chile as speaker or expert jury.



**Francois R. Martelet**  
**Vivesto**



Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat & late stage cancers.

It has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is developed for ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Vivesto has a proprietary drug delivery technology designed to improve solubility, efficacy and safety.



**Ulrik Cordes**  
**Cbio A/S**



Cbio A/S is a biopharmaceutical company. Cbio's mission is to develop and bring next-generation cell-based immunotherapies to cancer patients worldwide to enable cancer cure. The focus is on so-called Tumor Infiltrating Lymphocyte – or TIL therapy, the most promising cell-based treatment for solid tumors. Cbio's transformative new TIL product – novoleucel – enables more patients to be treated due to its minimal invasiveness, a broader T-cell repertoire, short production time and industrial scalability without compromising yield. Cbio has a strong IP position for its highly differentiated product and has its own production capacity, a 1,000 m2 state-of-the-art facility.



**Adi Elkeles**  
**Trobix Innovation**



Trobix Bio is an Israeli-based biotechnology company. Their vision is to empower engineered phages using CRISPR and synthetic biology to modify microbiome traits and to develop life-changing therapeutics for better medicine. They are developing life changing therapeutics to treat patients that suffer from serious unmet need diseases such as superbug infections, cancer, and gut inflammation disorders, by empowering engineered phages using CRISPR and synthetic biology to modify microbiome traits.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Katja Ivanitskiy**  
**Sartar Therapeutics**

Sartar Therapeutics is a preclinical stage company developing a first-in-class precision medicine treatment for soft tissue sarcomas. In advanced disease the prognosis is poor, the 5-year survival for metastatic soft tissue sarcomas being 10 - 50 %, depending on tumour type, and there are only a limited number of treatment options available. McKinsey lists soft tissue sarcomas and GIST as commercially attractive cancers presenting significant remaining unmet need. They qualify for Orphan diseases.



**Mark Jackson**  
**Paras Biopharmaceuticals Finland Oy**

Located in the innovative and technology-advanced city of Oulu - Finland, Paras Biopharmaceuticals brings together a unique mix of world-class microbial biologics development technologies and a sound understanding of unmet medical needs for the development and production of "first in class" noble recombinant biologics. Founded in 2013, Paras Biopharmaceuticals has seen significant growth in its microbial recombinant therapeutics technology solutions.

The company prides itself at the forefront of providing solutions for unmet medical needs where treatments may not exist for certain diseases, or treatments exist but have become ineffective, or the delivery mechanisms or formulations are inadequate. Being a lean company, Paras Biopharmaceuticals has the flexibility to adapt to the demand in terms of availability and adequacy of treatments.



**Ole Peter Nordby**  
**Lytix**

Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient's immune system to fight cancer. The Company's technology is based on pioneering research in "host defense peptides" – nature's first line of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient's tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021.



# ANGLO NORDIC | LIFE SCIENCE CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Company Presentations Technology Investment Room



**Mike Karim**  
**Oxford Endovascular**

Oxford Endovascular Ltd is a spin-out from Oxford University, working to prevent brain haemorrhage by treating brain aneurysms, a condition that affects 1 in 50 persons. OxiFlow™ is a novel, next generation flow-diverter, that diverts blood flow away from intracranial aneurysms at risk of rupture. Using 'Origami Engineering' it places more accurately and safely than existing devices, reducing the risk of complications. It conforms better to blood vessels making more patients treatable. Invented by a world-renowned physician who pioneered the treatment of aneurysms over the last 30 years and an expert in 'origami engineering', it has patents in Europe, US, China & Japan. The company has raised over \$20m to support its development including winning a prestigious Horizon 2020 grant from the European Union and an Innovate UK grant, following extensive due diligence by medical, industry and investor experts. Targeting a market over \$1 billion, that is growing rapidly, Oxford Endovascular is poised for significant increased value as it addresses unmet clinical needs.



**Abhishek Shah**  
**Wellthy Therapeutics**

Wellthy Therapeutics are an Active Digital Ingredient company, using Software as a Medical Device (SaMDs) to solve the unmet needs of the patient. Wellthy Therapeutics commercialise as a companion or combination to the drug, to intersect Real World Outcomes with business ROI. They have been fortunate to already partner with pharma and Med.tech to bring combination/companion SaMD solutions to market in 3 countries, through which they have impacted ~100,000 patients already (1% of the way to our 10m impact goal).



**Peter Luebcke**  
**Curapel**

Curapel is a spin-out company from the world-renowned Dermatological Sciences research group of the University of Manchester. They develop safe and clinically validated, 'turn key' Integrative Dermatology products for D2C and licensing. Curapel's products and pipeline target the multi \$billion markets of adult & paediatric eczema, psoriasis, skin pigmentation disorders, skin microbiome & gut-skin axis, dry, sensitive skin, transdermal delivery. Technologies and products are protected by a Curapel-owned portfolio of patents & trademarks. The company is raising investment to expand D2C eCommerce sales and also secure global licensing agreements across OTC and cosmetic skin-health applications. We will recruit new executives across the sales & marketing and licensing categories to grow the business for an envisaged exit within 5 years.



**Axel Behrens**  
**Flash Diagnostics**

FLASH diagnostics uses proprietary, patent-protected three-dimensional tissue analysis technology to revolutionise the detection and diagnosis of metastatic cancer.



# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Joe Healey**  
**Nanosyrinx**

Many drugs need access to the interiors of cells, where the machinery of life is busy going about its tasks.

Many drugs suffer from efficacy problems however, it is very difficult to ensure the 'active ingredient' gets to where it is needed most. One of the primary culprits in causing this problem, is the membrane that surrounds every one of the billions upon billions of cells in the body.

NanoSyrinx is an innovative startup being built around an entirely novel way to overcome this issue, with the vision of fundamentally revolutionising how medicines are administered - on a nanoscopic scale.

They are leveraging naturally occurring, protein 'nanosyringes', to encapsulate and deliver therapeutic payloads in a cell specific manner, with nano-scale accuracy.



**Marta Toro**  
**Parkinsons**

Parkinsons is a digital solution that comes in the form of an app and offers data training in a variety of disciplines.



13:00 - 13:45

## Panel Discussion: RNA in the Spotlight



**Donna Hackett**  
**Head of Commercial Translation**

Donna has more than 25 years' experience with a successful track record of wealth creation in commercialising life science technologies through deals including partnering of products and technologies and venture financing. Previous roles include being on part of the executive team of Abzena plc as SVP IP Commercial and Legal Affairs, where she was responsible for the legal IP and transactional activity, and COO and executive board member of Stabilitech.

At UCL, she led BioPharm Technology Transfer and was instrumental in starting BioVex with the academic founders, securing the first three rounds of funding. BioVex was sold to Amgen for \$1 billion and the product is on the market.



**Ralph Lindemann**  
**Global Head, Translational and Biomarker Research, TIP Oncology & Immunoncology, Merck**

Ralph is a biochemist by training and has been involved in cancer research for more than 20 years. Following postdoctoral training at Peter MacCallum Cancer Centre in Melbourne, Australia and research studies at German Cancer Research Center in Heidelberg, Ralph joined Merck Oncology R&D in 2008 and held various roles, most recently Head, Strategy and Alliances in Oncology & Immunology Discovery. He led Merck's Cancer Metabolism program and with co-workers, conceptualized and completed fundraising for IMMUCan, one of Europe's largest immunoncology profiling consortia. Ralph has been a long-standing collaborator of the Merck Ventures team and was CSO on-assignment for a Merck Venture portfolio company.



**Steven Powell**  
**CEO, eTheRNA**

Steven is a Ph.D. microbiologist with Large Cap Pharma experience. He was a former CEO of both public and private biotech companies. He was previously a partner at Glide Healthcare Partners.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Oliver Rausch**  
Chief Scientific Officer, STORM Therapeutics

Oliver has overall responsibility for developing STORM's target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series A investment that launched STORM, and subsequently joined the company full time in October 2016.

Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused collaboration programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company's acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008.

Oliver has over 15 years' drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.

13:45 - 15:30

## Company Presentations Biotech Investment Room



**Chaired by Kam Dhaliwal**  
bit.bio

bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines for every patient, everywhere. This is possible with our proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.



**George Frodsham**  
MediSieve

London-based startup developing Magnetic Haemofiltration, MediSieve is a platform therapy that enables doctors to remove specific substances directly from the bloodstream of patients. Wide range of potential applications. First product treats acute hyperinflammation through the rapid and specific removal of IL-6 from Critical Care patients. Second product will be enabling AAV gene therapy.



**Edvard Christian Fuglset Dahl**  
Pharma Holdings AS

In a world with an increasing number of resistant and difficult-to-treat microbes, Pharma Holdings has set off to develop new drugs that are rapid acting and with a low propensity towards resistance development. Our new generation cationic peptide is the result of world-class research in the field of lytic peptides. Further, our compound LTX-109 is derived from a naturally occurring peptide which, together with the low drive towards resistance development, ensures a sustainable way of fighting off infections and currently threatening the global health.



# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Robert Haigh**  
**Outrun Therapeutics**



Outrun Therapeutics (OTX) is an early-stage biotech company aiming to become the world leader in first-in-class E3 ligase inhibitors targeting a range of diseases including neurodegeneration, cancer and autoimmune disorders. OTX is a spinout from the laboratory of Prof Satpal Virdee at the University of Dundee's world-renowned MRC Protein Phosphorylation and Ubiquitylation unit. OTX utilises a proprietary platform technology that allows direct measurement of selected E3 ligase activity in a high-throughput format, thereby removing the bottlenecks normally associated with E3 ligase inhibitor discovery. This approach is completely distinct from targeted degradation strategies; the inhibition of specific E3 ligase activity will stabilise proteins whose loss drives disease. Using this technology, OTX is assembling a product pipeline of novel drugs to treat life-threatening diseases.



**Nara Daubeney**  
**Phaim Pharma**



Phaim is dedicated to developing curative treatments for auto-immune diseases. The company is developing a range of novel therapeutic innovations including an exciting new therapy to treat and prevent diabetes and a predictive kit for first-degree relatives. Our long-term goal is the broadening of our platform approach to other autoimmune diseases through our active R & D programme.



**Bo Rode Hansen**  
**Scandion**



Scandion Oncology discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are world leaders in reverting the cancer's resistance against treatment, thus making the treatment work better and longer thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.



**Juan Perez Villar**  
**Leadartis**



Leadartis is a preclinical stage immuno-oncology company engaged in the development of proprietary therapeutic bispecific antibodies. Our lead candidate is undergoing safety primate studies and is expected to enter clinical trials. Trimerbody® is a registered trademark and both platform and product candidates are protected by international patents.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Company Presentations Technology Investment Room



**Brian Burke**  
**Edity Therapeutics Ltd**

Edity Therapeutics is an Israeli company focusing on the development of a novel therapeutic platform based around the immune synapse as a mechanism for reprogramming diseased cells back to health. Founded in 2020, the company has raised over \$7M in seed funding and is planning to secure Series A funding in the coming 12 months.



**Hamina Patel**  
**InProTher**

InProTher is an early-stage biotech from Copenhagen (BioInnovation Institute). They are developing effective cancer vaccines based on Human EndoRetroviruses (HERVs) using Adeno and RNA vectors. They have exciting in vivo PoC and preclinical data in multiple oncology indications. They aim to enter FIH in 2023.



**Nathalie Lahet**  
**REGEMAT 3D**

REGEMAT 3D develops bioprinters and bioreactors for research and science applied to regenerative medicine, tissue engineering and drug discovery. We also supply the necessary bioinks and consumables for the research.



**Youness Quahid**  
**Mirmax**

Mirmax Biosens is a biotechnology company that focused on the diagnostic area. Our company has a patented Next Generation PCR Diagnostic Platform that improves the clinical identification of human diseases. Our platform fits the development of different kits for the molecular diagnosis of pathologies. MIRNAX is currently developing a new kit for the early diagnosis of prostate cancer, based on a miRNA biomarker for differential diagnosis in patients with elevated PSA levels.



**Isabel Portero**  
**Biohope**

Biohope, founded in 2015, is an early commercial stage private biotech and IT company developing novel pharmacological IVD tools to personalize and optimize the medical treatment of chronic inflammation in patients undergoing treatment with immunosuppressant and/or immunomodulating therapies.



**Elena Rivas**  
**ARRAYS FOR CELL NANODEVICES**

A4Cell provides a new kind of products for live cell imaging based on the concept of lab-in-a-cell. Their company has developed the SPACHIP® technology enabling analysis of intracellular parameters of cell physiology and stress in real time. SPACHIP® devices are silicon oxide microparticles functionalized with fluorescent detection probes that can be used with image analyzers to study cells over extended periods of time without causing cytotoxicity.



# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

16:00 - 16:45

## Panel Discussion: Anticipated Developments in Neuroinflammation Therapies



Chaired by **Richard Staines**  
**BioWorld**

Richard is a Life Science Writer for BioWorld and was previously the news editor for pharmaphorum. Richard has been a journalist since the late 90s and has written for websites, newspapers and magazines. He has always had an interest in health and has been writing about the pharma industry since 2010. His coverage has included stories about market access, the impact of the Greek financial crisis on the healthcare system and pharma pricing in the UK. Since joining pharmaphorum he has covered stories on topics including regulation, mergers and acquisitions, and the latest clinical developments.



**Alan Watt**  
**Chief Scientific Officer, NodThera**

Alan has over 30 years of experience in drug discovery and development in both the pharmaceutical and biotechnology sectors. His previous roles include serving as vice president of therapeutics at Bicycle Therapeutics, as chief operating officer and executive vice president of R&D at Trident Pharmaceuticals, and as chief executive officer of Xenovium. Alan formerly led inflammasome discovery at GlaxoSmithKline, where he established the Pattern Recognition Receptor Discovery Performance Unit within GSK's Immuno-Inflammation Centre of Excellence for Drug Discovery (CEDD). He also previously served as head of drug metabolism and in vivo pharmacology at Merck. Alan holds a Bachelor of Science in chemistry from the University of Southampton, a Ph.D. in drug metabolism from the University of Hertfordshire and an MBA from the Open Business School. He has over 50 peer-reviewed scientific publications.



**Stefan Lohmer**  
**CEO, Axxam SpA**

Stefan Lohmer is a co-founder and Chief Executive Officer of Axxam, as well as Board Member of Rewind Therapeutics NV. Prior to founding Axxam, he was head of the assay development unit at the Bayer Research Centre in Milan and the Head of Genomics worldwide for Bayer AG. He was responsible for generating and managing Bayer's external genomic alliances with Millennium and Lion Bioscience. Stefan Lohmer joined Bayer in 1992. He holds a degree in Molecular Biology and Biochemistry from the University of Cologne and completed his PhD at the Max Planck Institute for Plant Breeding in Cologne.



**Hugh Nuthall**  
**Senior Director, Search & Evaluation - Neuroscience, Eli Lilly and Company**

Highly experienced drug discovery scientist with a demonstrated record of success working in the pharmaceuticals industry. Experienced leader of neuroscience drug discovery programs and multidisciplinary teams. Focused on internal and external innovation for neurodegenerative diseases. Developed research & drug discovery partnerships with Academic, Biotechnology and Charity sectors. Strong research professional skilled in Neuroscience, Biochemistry, Biotechnology, Molecular Biology, In Vitro, In Vivo, and Drug Discovery.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



## **Dr. Maria Teresa Ferretti**

**Co-Founder & Chief Scientific Officer, Women's Brain Project**

Dr. Maria Teresa Ferretti is a neuroimmunologist, science advocate and external teacher at the Medical University of Vienna with over 10 years of international experience in the field of Alzheimer's disease and a unique expertise on sex and gender differences.

She has a Master in Pharmaceutical Chemistry from the University of Cagliari and obtained a PhD in Pharmacology and Therapeutics at McGill University (Montreal, Canada). Dr. Ferretti worked at Nitsch's lab at the University of Zurich (Switzerland) as postdoc and group leader on the role of the immune system in Alzheimer's.

2016, Maria Teresa co-founded the non-profit organization called 'Women's Brain Project' (WBP), that studies sex- and gender-sensitive precision medicine for brain and mental diseases (e.g. Alzheimers, migraine, depression).

Her work as WBP Chief Scientific Officer has led to several scientific publications in leading journals including Nature, Science and PNAS, three TED-x talks, and coverage by both the national (Sonntagszeitung, SwissInfo, NZZ, Le Temps) and the international press (including BBC, The Independent, Sciences et Avenir, Financial Times, La Stampa, ELLE Italy).

As WBP Chief Scientific Officer she is a sought-after speaker, and gives regular talks, lectures and presentation, both at scientific and lay public meetings. She is a faculty member of the Course for Advance Studies (CAS) on gender medicine at University of Zurich (Switzerland) and the editor of the book 'Sex differences in Alzheimer's Disease' published by Elsevier.



## **Rob Pinnock**

Director - External Innovation, Biogen

16:45 - 17:45

### **Panel Discussion: If I knew then what I know now**



## **Chaired by Mike Ward**

**Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate**

Mike Ward serves as Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate. As both an award-winning journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.

# ANGLO NORDIC | LIFE SCIENCE CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Carolyn Porter**  
**CEO, Cytoseek**

Carolyn brings 20 years of leadership experience from a career spanning start-up, biotech and pharma companies. In the start-up arena she led the formation of 16 companies raising £52M cumulatively in seed financing while in a previous role at Oxford University. Carolyn has also held Board positions in several biotech companies. Prior to joining CytoSeek in January 2020 Carolyn was Chief Business Officer of OxStem Ltd, a biotech developing therapies targeting stem cells. She has also held senior Business Development roles in large pharma (Novartis) and biotech (Chiron) companies working on in/out licensing transactions, acquisitions and strategic alliances with deal values in excess of \$1bn. Carolyn's previous career included working in Corporate Finance at Ernst & Young and as a post-doctoral researcher in Oxford University. She has an MBA from Warwick University and a PhD in Immunology from Trinity College Dublin.



**Georg Buchner**  
**Group Chief Business Officer, Helsinn Group**

Georg joined Helsinn in 2019 with over 15 years' experience in the life science industry, ranging from start-ups to multi-national biopharma companies.

Leading knowledge and expertise in M&A, licensing, alliance management, strategy and venture capital funding.

Holds an MBA from The University of Cambridge and PhD in Molecular and Developmental Biology from Kings College London.



**Catherine Moukheibir**  
**Non Executive Board Member**

Ms. Moukheibir most recently served as chief executive officer of MedDay Pharmaceuticals, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chairman of the board of directors of MedDay from April 2016 to January 2021. Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to December 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007. Ms. Moukheibir currently serves on the board of directors and chairs the audit committee of Orphazyme A/S, Ironwood Pharmaceuticals and CMR Surgical. She also held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA, Creabilis S.A., GenKyoTex S.A., Kymab Group Ltd and Zealand Pharma A/S.

Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University. Ms. Moukheibir's long leadership career in the biopharmaceutical industry, as well as her deep background in international finance, provide her with valuable business and financial expertise in support of our corporate objectives.

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022



**Deborah Spencer**

**Innovation & Business Partnerships Manager; University Lead, UK Industrial Strategy, University of Oxford**

Deborah has a bachelor's degree from the University of London, an E\*MBA from Copenhagen Business School, a MSC from the University of Edinburgh and a PhD from Dundee Business School focused on Life Sciences Intermediaries. While in Denmark Deborah worked for PwC and was a founding member of the newly created Environmental Management Unit focused on Green Accounting.

Deborah is responsible for developing activities under the Industrial/Innovation Strategy across the University of Oxford and is Deputy Head of the Innovation & Business Partnerships Team where she engages with industry to build strategic partnerships that leverage academic research strengths. She previously worked at the Oxford Local Enterprise Partnership (OxLEP) as the Life Sciences specialist for the Region and helped to establish the Health Tec Cluster at the Harwell Science Campus as part of her remit. Deborah has also worked in senior positions at the Universities of Edinburgh and Dundee, and for a couple of the UK Research Councils. While in Edinburgh, she led on the establishment of a new genomics centre. She has also been involved in three company spinouts and in the creation of two fee- for- service entities from the university base. In Oxford she helped spearhead the funding for the £30m Nucleic Acid Therapies Accelerator (NATA) and helped to facilitate Brazil in joining the Oxford vaccine efforts. Many of those from the sector will know her from her leadership of the BioDundee cluster organisation, a hugely successful not-for-profit.

Deborah has many connections with national and international leaders from industry, the investment community, academia, intermediaries and government organisations.



**Khatereh Ahmadi**

**Head of Search and Evaluation Team, European BD&L Hub, MSD**

17:45 - 17:50

**Conclusions**

16:45 - 17:45

Drinks Reception kindly sponsored by

**BJ** | **Barrington  
James**

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Charity of the Year

We are delighted to support Cambridge Rare Disease Network (CRDN) as the Anglonordic Life Science Conference Charity of the Year for 2022. Delegates will have the opportunity to meet CRDN during the conference programme including 1:1 networking and the exhibition. Plus have your very own caricature sitting with Clive Goddard, located in the Exhibition, in aid of CRDN #thinkrare!

### About the Cambridge Rare Disease Network

Cambridge Rare Disease Network is a platform for change. It is the infrastructure that unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare diseases. By sharing knowledge and experience, and working together, the journey towards better diagnosis, treatment and support for patients and their families is smoother and more certain.

### Charity Aims

#### PROMOTING CROSS-SECTOR COLLABORATION

We bring together all stakeholder groups involved in rare diseases in a spirit of collaboration and understanding by providing opportunities to share, learn, engage and be innovative together to improve the lives of those affected by rare disease. We ensure that the voice of people living with rare conditions is at the heart of all our discussions, events and activities as experts and valued partners. Cambridge Rare Disease Network

#### SHARING CAMBRIDGE EXPERTISE WITH THE WORLD

We create and deliver exceptional, engaging and thought-provoking educational events to help address knowledge gaps and to raise awareness about rare disease amongst health professionals, academics, industry, policy makers and the wider public. We provide a platform for UK and international thought leaders and showcase the potential of the Cambridge Cluster – the University of Cambridge, Biomedical Campus and vibrant biotech community on our many Science Parks. Events have powerful patient voices and advocacy groups at their heart. Cambridge Rare Disease Network

#### BUILDING A LOCAL RARE DISEASE COMMUNITY

We support children and families living with rare disease in our local community by providing activities to reduce isolation, offer peer support, build a community and give them a place to belong. We develop opportunities for adults living with rare conditions to connect, share experiences and form a collective voice to raise awareness and improve local services.



# YOUR PARTNER IN INNOVATION.



You're working to drive life sciences innovation. McDermott's team works alongside you in your pursuit of growth and life sciences progress. How can we help fuel your mission?

[MWE.COM/LIFESCIENCES](https://www.mwe.com/lifesciences)



**McDermott  
Will & Emery**

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Exhibitors

### BioPartner UK

#### Stand 1

BioPartner UK is the independent, accredited trade organisation that promotes international partnering for trade, investment and collaborations with UK life science enterprises. BioPartner's UK Delegations promote the UK presence at international conferences. They work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for their members and UK companies travelling with outward delegations. BioPartner also provides entry fee discounts for all UK-based organisations.



### Brain Tumour Research

#### Stand 2

Brain Tumour Research are the only national charity in the UK focused on finding a cure for all types of brain tumours through campaigning to increase the national investment in brain tumour research to £35 million per year, while fundraising to create a network of seven sustainable Brain Tumour Research Centres of Excellence across the UK.



### Invest in Denmark

#### Stand 3

Invest in Denmark offers tailored advice to foreign companies, who are considering investing or establishing business or research activities in Denmark, all free of charge and in full confidentiality.



### ICEX - Invest in Spain

#### Stand 4

Invest in Spain is an executive division of ICEX Trade and Investment, a publicly owned business-oriented entity of the Ministry of Industry, Trade and Tourism's Secretary of State for Commerce. Their mission is to promote foreign direct investment (FDI) in Spain and to support business owners and entrepreneurs that want to set up their companies in Spain.



### Cambridge Rare Disease Network

#### Stand 5

Cambridge Rare Disease Network (CRDN) is a platform for change. It is the infrastructure that unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare diseases. By sharing knowledge and experience, and working together, the journey towards better diagnosis, treatment and support for patients and their families is smoother and more certain. CRDN are the Anglonordic Life Science Conference Charity of the Year for 2022.



# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Yorkshire Humberside AHSN

### Stand 6



Yorkshire & Humber AHSN is one of 15 AHSNs set up by NHS England to operate as the key innovation arm of the NHS. Across the country AHSNs act as a bridge between health care providers, commissioners, academia and industry. By connecting these sectors, we help to build a pipeline of solutions for the NHS from research and product development through to implementation and commercialisation. Locally they work in partnership with their regional health and care community and develop projects, programmes and initiatives that reflect the diversity and meet the needs of their local populations and health care challenges.

## Clive Goddard - Cartoonist

### Stand 7



Professional cartoonist, published in Private Eye, Prospect, Punch, Playboy etc, as well as commissions for the BBC, American Express, Oxford University Press, Specsavers & many others. An illustrator of non-fiction children's books for Scholastic including the 'Horribly Famous' series, 'Bonkers Books' and the 'Totally' series. A writer of children's books including the award-winning 'Fintan Fedora the World's Worst Explorer' series. Clive will be available to take sittings during the conference with a percentage of sales going to support our Conference Charity of the Year - Cambridge Rare Disease Network with caricatures sporting zebra stripes to raise awareness of Rare Diseases #ThinkRare.

## Scantox

### Stand 8



Scantox is a specialised pre-clinical contract research organisation within pharmacology, toxicology and histopathology, with a mission to improve the health of people. Based on decades of experience, we are a trusted partner to industry clients around the world, and considered a global leader within minipig toxicology. All Scantox experts are passionate about our common vision, and all our processes are rooted in dedication and guided by a strong sense of purpose. A GLP-accredited company.

## Barrington James

### Stand 9



Barrington James are your global and award winning Life Science recruitment experts. Having grown in both size and reputation since 2002, we now operate across three continents and are at the forefront of recruiting top talent for the most innovative Biotech, Pharmaceutical and Medical Device companies.

## ProtaGene

### Stand 10




ProtaGene is a world-leading analytic CRO partner for the biopharmaceutical and gene and cell therapy industries.

# Analytical Excellence

Complete Analytic Solutions for  
Protein Biologics and Cell and Gene Therapeutics

Advanced CMC and Pre/Clinical Applications for  
Protein, DNA, RNA, and Gene Editing Products






# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

COUNTY HALL, LONDON • 04 - 05 MAY 2022

## Exhibitor Stands

1. BioPartner UK
2. Brain Tumour Research
3. Invest in Denmark
4. ICEX
5. Cambridge Rare Disease Network
6. Yorkshire Humberside AHSN
7. Goddard Creative
8. Scantox
9. Barrington James
10. Protogene



FOUNDING SPONSOR



PARTNERING LOGIN



GOLD SPONSORS



Barrington  
James



McDermott  
Will & Emery

[www.anglonordiclifescience.com](http://www.anglonordiclifescience.com)



etcvenues | Password: wif3052



@Anglonordic